

OCREVUS ZUNOVO™ Vials 920 mg/23ml

Version 1.0 Revision Date: 04-19-2024 Date of last issue: -
Date of first issue: 04-19-2024

SECTION 1. IDENTIFICATION

Product name : OCREVUS ZUNOVO™ Vials 920 mg/23ml

Product code : RO496-4913/F09

Common name(s), syno- : Ocrevus SC 40 mg/ml
nym(s) of the substance

Manufacturer or supplier's details

Company name of supplier : Genentech, Inc.

Address : 1 DNA Way
South San Francisco, CA 94080
USA

Telephone : 001-(650) 225-1000

E-mail address : info.sds@roche.com

Emergency telephone

Emergency telephone num- : US Chemtrec phone (800)-424-9300
ber

Recommended use of the chemical and restrictions on use

Recommended use : Formulated pharmaceutical active substance

Restrictions on use : For professional users only.

SECTION 2. HAZARDS IDENTIFICATION**GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)**

Not a hazardous substance or mixture.

GHS label elements

Not a hazardous substance or mixture.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Ocrelizumab	637334-45-3	4
Trehalose (D+)-, 2H2O	6138-23-4	9.1
Sodium acetate trihydrate	6131-90-4	0.22
L-Methionine	63-68-3	0.15
Sorbitan, monododecanoate,	9005-64-5	0.06

OCREVUS ZUNOVO™ Vials 920 mg/23ml

Version
1.0

Revision Date:
04-19-2024

Date of last issue: -
Date of first issue: 04-19-2024

poly(oxy-1,2-ethanediyl) derivs.		
Acetic acid	64-19-7	0.02
Hyaluronidase	757971-58-7	0.0017
Water	7732-18-5	> 86

SECTION 4. FIRST AID MEASURES

- General advice : Do not leave the victim unattended.

- If inhaled : Move to fresh air.
If unconscious, place in recovery position and seek medical advice.
If symptoms persist, call a physician.

- In case of skin contact : If on skin, rinse well with water.

- In case of eye contact : Immediately flush eye(s) with plenty of water.
Remove contact lenses.
Protect unharmed eye.
If eye irritation persists, consult a specialist.

- If swallowed : Keep respiratory tract clear.
Do not give milk or alcoholic beverages.
Never give anything by mouth to an unconscious person.
If symptoms persist, call a physician.
Rinse mouth with water.

- Most important symptoms and effects, both acute and delayed : None known.

- Notes to physician : The first aid procedure should be established in consultation with the doctor responsible for industrial medicine.

SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

- Specific hazards during fire fighting : No information available.

- Hazardous combustion products : Carbon oxides
In case of fire hazardous decomposition products may be produced such as:
Carbon monoxide
Nitrogen oxides (NOx)
Sulfur oxides

- Further information : Standard procedure for chemical fires.
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

OCREVUS ZUNOVO™ Vials 920 mg/23ml
Version
1.0Revision Date:
04-19-2024Date of last issue: -
Date of first issue: 04-19-2024

Special protective equipment : Wear self-contained breathing apparatus for firefighting if necessary for fire-fighters

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Refer to protective measures listed in sections 7 and 8.

Environmental precautions : Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Wipe up with absorbent material (e.g. cloth, fleece).
Keep in suitable, closed containers for disposal.

SECTION 7. HANDLING AND STORAGE

Advice on protection against fire and explosion : Normal measures for preventive fire protection.

Advice on safe handling : For personal protection see section 8.
Smoking, eating and drinking should be prohibited in the application area.

Conditions for safe storage : Electrical installations / working materials must comply with the technological safety standards.

Further information on storage conditions : See label, package insert or internal guidelines

Materials to avoid : No materials to be especially mentioned.

Storage temperature : Protected from heat and light

Further information on storage stability : No decomposition if stored and applied as directed.

Packaging material : Suitable material: Stainless steel, glass, Vials

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Ocrelizumab	637334-45-3	IOEL	0.02 mg/m ³	Roche Industrial Hygiene Committee (RIHC)
Hyaluronidase	757971-58-7	IOEL	0.00006 mg/m ³	Roche In-

OCREVUS ZUNOVO™ Vials 920 mg/23ml

Version
1.0

Revision Date:
04-19-2024

Date of last issue: -
Date of first issue: 04-19-2024

				Industrial Hygiene Committee (RIHC)
--	--	--	--	-------------------------------------

Engineering measures : No data available

Personal protective equipment

Respiratory protection : No personal respiratory protective equipment normally required.

Hand protection

In case of contact through splashing:
 Material : Nitrile rubber
 Break through time : > 30 min
 Glove thickness : > 0.11 mm

In case of full contact:
 Material : butyl-rubber
 Break through time : > 480 min
 Glove thickness : > 0.4 mm

Remarks : Wear appropriate protective gloves to prevent skin contact. Replace torn or punctured gloves promptly.

Eye protection : Safety glasses

Skin and body protection : Protective suit

Hygiene measures : Handle in accordance with good industrial hygiene and safety practice.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : Aqueous solution, Clear liquid, sterile

Color : colorless

Odor : No data available

Odor Threshold : No data available

pH : 5.3

Melting point/range : No data available

Boiling point/boiling range : No data available

OCREVUS ZUNOVO™ Vials 920 mg/23mlVersion
1.0Revision Date:
04-19-2024Date of last issue: -
Date of first issue: 04-19-2024

Evaporation rate	:	No data available
Self-ignition	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Solubility(ies)		
Water solubility	:	completely miscible
Solubility in other solvents	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, dynamic	:	No data available
Viscosity, kinematic	:	No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	No dangerous reaction known under conditions of normal use.
Chemical stability	:	Stable under normal conditions. Proteins are temperature-sensitive; the thermal denaturation has an impact on quality but does not affect Plant and Process Safety; during decomposition no flammable gas, no organic peroxide and no oxidising substances are created
Possibility of hazardous reactions	:	Stable under recommended storage conditions. No hazards to be specially mentioned.
Conditions to avoid	:	No data available
Incompatible materials	:	No data available
Hazardous decomposition products	:	No data available

OCREVUS ZUNOVO™ Vials 920 mg/23mlVersion
1.0Revision Date:
04-19-2024Date of last issue: -
Date of first issue: 04-19-2024

SECTION 11. TOXICOLOGICAL INFORMATION**Acute toxicity**

Not classified based on available information.

Components:**Trehalose (D+)-, 2H₂O:**

Acute oral toxicity : LD50 (Rat): 16,000 mg/kg

Ocrelizumab:

Acute oral toxicity : Remarks: Not bioavailable by oral administration

Acute toxicity (other routes of administration) : LD0 (cynomolgus monkey): 100 mg/kg
Application Route: i.v.
GLP: yes**Hyaluronidase:**

Acute oral toxicity : Remarks: Not bioavailable by oral administration

Skin corrosion/irritation

Not classified based on available information.

Components:**Hyaluronidase:**

Remarks : This information is not available.

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Hyaluronidase:**

Remarks : This information is not available.

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:**Hyaluronidase:**

Remarks : May cause sensitization of susceptible persons by skin contact or by inhalation of dust.

OCREVUS ZUNOVO™ Vials 920 mg/23ml

Version
1.0

Revision Date:
04-19-2024

Date of last issue: -
Date of first issue: 04-19-2024

Germ cell mutagenicity

Not classified based on available information.

Carcinogenicity

Not classified based on available information.

IARC No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Not classified based on available information.

Components:

Ocrelizumab:

Effects on fetal development : Species: cynomolgus monkey
Application Route: i.v.
Dose: 100 milligram per kilogram
Result: No teratogenic effects., No embryotoxic effects.

STOT-single exposure

Not classified based on available information.

Components:

Hyaluronidase:

Assessment : The substance or mixture is not classified as specific target organ toxicant, single exposure.

STOT-repeated exposure

Not classified based on available information.

Components:

Hyaluronidase:

Assessment : The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

Repeated dose toxicity

Components:

Hyaluronidase:

Species : cynomolgus monkey
NOAEL : mg/kg/w, 2
Application Route : s.c.
Exposure time : 39 weeks

OCREVUS ZUNOVO™ Vials 920 mg/23mlVersion
1.0Revision Date:
04-19-2024Date of last issue: -
Date of first issue: 04-19-2024**Aspiration toxicity**

Not classified based on available information.

Components:**Hyaluronidase:**

No data available

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Trehalose (D+)-, 2H2O:**Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 100 mg/l
Exposure time: 96 h
Test Type: static testToxicity to fish (Chronic toxicity) : NOEC (Danio rerio (zebra fish)): 100 mg/l
Exposure time: 96 d**Ecotoxicology Assessment**

Acute aquatic toxicity : This product has no known ecotoxicological effects.

Chronic aquatic toxicity : This product has no known ecotoxicological effects.

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to the environment : No data available

Ocrelizumab:Toxicity to fish : LC50 (Poecilia reticulata (guppy)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
GLP: yes
Remarks: nominal concentrationToxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Test Type: Immobilization
Method: OECD Test Guideline 202
GLP: yes
Remarks: nominal concentrationNOEC (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Test Type: Immobilization
Method: OECD Test Guideline 202
GLP: yes
Remarks: nominal concentration

OCREVUS ZUNOVO™ Vials 920 mg/23ml

Version 1.0 Revision Date: 04-19-2024 Date of last issue: -
Date of first issue: 04-19-2024

Toxicity to algae/aquatic plants : ErC50 (Desmodesmus subspicatus (green algae)): > 100 mg/l
Exposure time: 72 h
Test Type: Growth inhibition
Method: OECD Test Guideline 201
GLP: yes
Remarks: nominal concentration

EyC50 (Desmodesmus subspicatus (green algae)): > 100 mg/l
Exposure time: 72 h
Test Type: Growth inhibition
Method: OECD Test Guideline 201
GLP: yes
Remarks: nominal concentration

Hyaluronidase:

Ecotoxicology Assessment

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to the environment : No data available

Persistence and degradability

Components:

Trehalose (D+)-, 2H2O:

Biodegradability : aerobic
Inoculum: activated sludge, non-adapted
Biochemical oxygen demand
Result: Readily biodegradable.
Biodegradation: 73 %
Method: OECD Test Guideline 301A
Remarks: The 10 day time window criterion is not fulfilled.

aerobic
Inoculum: activated sludge, non-adapted
Dissolved organic carbon (DOC)
Result: Readily biodegradable.
Biodegradation: 98 %
Method: OECD Test Guideline 301A

Ocrelizumab:

Biodegradability : aerobic
Theoretical oxygen demand
Result: Readily biodegradable.
Biodegradation: 93 %
Exposure time: 28 d
Method: OECD Test Guideline 301F
GLP: yes

OCREVUS ZUNOVO™ Vials 920 mg/23ml

Version
1.0

Revision Date:
04-19-2024

Date of last issue: -
Date of first issue: 04-19-2024

Hyaluronidase:

Biodegradability : Result: Globular proteins are generally well biodegradable

Bioaccumulative potential

Components:

Trehalose (D+)-, 2H2O:

Partition coefficient: n-octanol/water : Remarks: No data available

Ocrelizumab:

Partition coefficient: n-octanol/water : Remarks: No data available

Hyaluronidase:

Partition coefficient: n-octanol/water : Remarks: No data available

Mobility in soil

No data available

Other adverse effects

Product:

Ozone-Depletion Potential : Regulation: 40 CFR Protection of Environment; Part 82 Protection of Stratospheric Ozone - CAA Section 602 Class I Substances
Remarks: This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

Components:

Hyaluronidase:

Additional ecological information : No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

- Waste from residues : Can be disposed as waste water, when in compliance with local regulations.
- Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
Do not re-use empty containers.

OCREVUS ZUNOVO™ Vials 920 mg/23mlVersion
1.0Revision Date:
04-19-2024Date of last issue: -
Date of first issue: 04-19-2024

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable

Domestic regulation**49 CFR**

Not regulated as a dangerous good

Special precautions for user

Remarks : Not dangerous goods in the meaning of ADR/RID, ADN, IMDG-Code, ICAO/IATA-DGR

SECTION 15. REGULATORY INFORMATION**CERCLA Reportable Quantity**

Listed substances in the product are at low enough levels to not be expected to exceed the RQ

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : No SARA Hazards**SARA 313** : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.**Clean Air Act**

This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCM Intermediate or Final VOC's (40 CFR 60.489).

OCREVUS ZUNOVO™ Vials 920 mg/23ml

Version
1.0

Revision Date:
04-19-2024

Date of last issue: -
Date of first issue: 04-19-2024

Clean Water Act

The following Hazardous Substances are listed under the U.S. CleanWater Act, Section 311, Table 116.4A:

Acetic acid	64-19-7	>= 0 - < 0.1 %
-------------	---------	----------------

The following Hazardous Chemicals are listed under the U.S. CleanWater Act, Section 311, Table 117.3:

Acetic acid	64-19-7	>= 0 - < 0.1 %
-------------	---------	----------------

This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307

This product does not contain any priority pollutants related to the U.S. Clean Water Act

US State Regulations

Massachusetts Right To Know

No components are subject to the Massachusetts Right to Know Act.

Pennsylvania Right To Know

Water	7732-18-5
Trehalose (D+)-, 2H2O	6138-23-4
Ocrelizumab	637334-45-3
Acetic acid	64-19-7

Maine Chemicals of High Concern

Hyaluronidase	757971-58-7
---------------	-------------

Vermont Chemicals of High Concern

Hyaluronidase	757971-58-7
---------------	-------------

Washington Chemicals of High Concern

Hyaluronidase	757971-58-7
---------------	-------------

The ingredients of this product are reported in the following inventories:

- AIIC : Not in compliance with the inventory
- DSL : This product contains the following components that are not on the Canadian DSL nor NDSL.
 - Ocrelizumab
 - Hyaluronidase
- NZIoC : On the inventory, or in compliance with the inventory
- ENCS : Not in compliance with the inventory
- ISHL : Not in compliance with the inventory
- KECI : Not in compliance with the inventory
- PICCS : Not in compliance with the inventory
- IECSC : Not in compliance with the inventory
- TCSI : Not in compliance with the inventory
- TSCA : Product contains substance(s) not listed on TSCA inventory.

OCREVUS ZUNOVO™ Vials 920 mg/23ml

Version
1.0

Revision Date:
04-19-2024

Date of last issue: -
Date of first issue: 04-19-2024

TECI : Not in compliance with the inventory

TSCA list


No substances are subject to a Significant New Use Rule.

No substances are subject to TSCA 12(b) export notification requirements.

SECTION 16. OTHER INFORMATION

Further information

NFPA 704:



HMIS® IV:

HEALTH	/	0
FLAMMABILITY	0	
PHYSICAL HAZARD	0	

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Pre-

OCREVUS ZUNOVO™ Vials 920 mg/23mlVersion
1.0Revision Date:
04-19-2024Date of last issue: -
Date of first issue: 04-19-2024

vention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Revision Date : 04-19-2024

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / Z8 / 2304